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heterocycle conjugate derived ureas and thioureas. They were characterized by physical and spec-
troscopical methods. Many of the analogues synthesized showed activity at the sub-micro molar
level. Introduction of different amino acids as linker and systematic variation of the substituents
on the aromatic ring revealed promising leads. In particular, compounds containing Glu and Tyr
as the linkers exhibited high antiglycating potency with IC50 1–4 lM as against the reference, rutin
with IC50 41.9 lM.
Conclusions: Compounds bearing halogen atoms emerged as the most active analogues and serve
as lead for future studies.
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Diabetes mellitus, especially type 2 diabetes is increasing at an
alarming rate and is considered as one of the main threats to
human health in the 21st century, in both developed and
developing nations [38]. Over the last 30 years, an enormous
number of studies have been dedicated to unravel the patho-
physiology of type 2 diabetes mellitus [28]. The AGEs are a
class of compounds which are generated during protein
glycation [26]. This process starts with the formation of an
initial adduct between the carbonyl group of reducing sugar
and the –NH2 group of a protein, a Maillard reaction.
Accumulation of AGEs is associated with aging, diabetes,
Alzheimer’s disease, renal failure and many other chronic
diseases [11].
Synthesis and evaluation of novel ureido/thioureido derivatives S249One very interesting and promising class of heterocycle is
piperazine and its derivatives. They have been extensively
investigated by the organic chemists due to their close associ-
ation with various types of biological activities. Moreover they
have wide clinical applications in the therapy of functional
diseases and exhibit insecticidal [4], antidiabetic [9], antimicro-
bial [3], acetyl cholinesterase inhibitors [10], antimalarial [23],
dopamine transporter [19], D2/D4 antagonist (He [12], MC4
receptor [2] and HIV-protease inhibitor [24]. On the other
hand, the therapeutical applications of amino acids have re-
ceived a considerable attention in respiratory physiology, car-
diology, renal failure, neurological disorders and congenital
defects. According to earlier studies, amino acids have also
proven to be antidiabetic, antiglycating and anticataractogenic
[27,34]. Several amino acids have found to be beneﬁcial in dia-
betes mellitus (DM) through their antiglycating functions [22].
Furthermore, previous reports from our research group have
revealed that conjugation of different amino acids/peptides
to various biologically active scaffolds and their derivatization
led to promising leads [35,29,31–33,25,37].
An unsymmetrically substituted urea is a common struc-
tural feature of many biological active compounds such as en-
zyme inhibitors and pseudopeptides [8]. Sulfonylureas have
found applications as oral antidiabetic drugs and as herbicides
[13]. However, urea can also be used as a protector of glyca-
tion, especially against ﬂuorescent advanced glycation end
products [14]. Moreover, recently unsymmetrically disubsti-
tuted urea derivatives, bis-Schiff bases of and also 3,5-di(tri-
ﬂuoromethyl)-1,2,4-triazolesulfonyl ureas and thioureas have
been reported as potent class of antiglycation and antidiabetic
agents, respectively [15,16,6].
Encouraged by the above facts, the present investigation in-
volves the synthesis and antiglycation studies of four series of
amino acid-2,3-dichlorophenyl piperazine conjugated urea/
thiourea derivatives.2. Materials and methods
2.1. General
Amino acids used were of L-conﬁguration unless otherwise
mentioned. TFA was purchased from Advanced Chem. Tech.
(Louisville, KY, USA). NMM and phenyl isocyanates/isothio-
cyanates were purchased from Sigma Chemical Co. (St. Louis,
MO). Melting points were determined on a Superﬁt melting
point apparatus (India) and are uncorrected. TLC was per-
formed on pre-coated silica gel plates (Kieselgel 60 F254, E.
Merck, Germany) with the solvent system comprising chloro-
form/methanol/acetic acid in the ratio 98:2:3 (Rf
a) and 95:5:3
(Rf
b) and the compounds on TLC were detected by iodine va-
pors. Solvents used were of reagent grade. IR spectra of the
compounds were recorded on Jasco Spectrometer (USA). 1H
NMR spectra were obtained on VARIAN 400 MHz instru-
ment (USA) using DMSO-d6 and the chemical shifts are re-
ported as parts per million (d ppm) using TMS as an
internal standard. Mass spectra were obtained on Bruker
(model HP-1100) (USA) electrospray mass spectrometer. Ele-
mental analysis was performed by using VARIO EL III Ele-
mentar (Germany). Bovine serum albumin was purchased
from Research Organics, Cleveland, while other chemicals
were purchased from Sigma Aldrich.2.2. Chemistry
2.2.1. General procedure for the conjugation of Boc–Xaa–OH
[where Xaa = Phe, Glu(OBzl), Tyr(2,6-Cl2-OBzl) and
Lys(Z)] to 1-(2,3-dichlorophenyl)piperazine (1–4)
1-(2,3-Dichlorophenyl)piperazineÆHCl was synthesized by pre-
viously reported method [21]. To Boc–Xaa–OH (0.01 mol)
dissolved in acetonitrile (10 mL/g of compound) and cooled
to 0 C was added NMM (1.10 mL, 0.01 mol). To this EDCI
(1.917 g, 0.01 mol) was added and stirred while maintaining
the temperature at 0 C. After stirring the reaction mixture
for 10 min at this temperature, HOBt (1.531 g, 0.01 mol) in
DMF (15 mL) was added slowly. The reaction mixture was
stirred for an additional 10 min and a pre-cooled solution of
2,3-dichlorophenyl piperazineÆHCl (2.68 g, 0.01 mol) and
NMM (1.10 mL, 0.01 mol) in DMF (25 mL) was added slowly.
After 20 min pH of the solution was adjusted to 8 by the addi-
tion of NMM and the reaction mixture was stirred over night
at room temperature. Acetonitrile was removed under reduced
pressure and the residual DMF was poured into about 500 mL
ice-cold 90% saturated KHCO3 solution and stirred for
30 min. The precipitated compound was extracted into chloro-
form and washed sequentially with 5% NaHCO3 solution
(3 · 20 mL), water (3 · 20 mL), 0.1 N cold HCl (3 · 20 mL)
followed by brine. The organic layer was dried over
anhydrous Na2SO4, the solvent was removed under reduced
pressure, triturated with ether, ﬁltered and dried to get the con-
jugates 1–4.
2.2.2. General procedure for the synthesis of ureido and
thioureido derivatives (8–55)
Each time, Boc–Xaa–PZN (0.150 g) [where Xaa = side chain
of Phe, Glu, Tyr and Lys] was stirred with 1.5 mL of TFA
for 45 min at room temperature. After completion of the reac-
tion (monitored by TLC), TFA was removed under vacuum,
triturated with dry ether, ﬁltered, washed with ether and dried
to obtain TFA.H–Xaa–PZN.
Further, TFA.H–Xaa–PZN (0.001 mol) was dissolved in
DMF (10 mL/g of compound), cooled to 0 C and NMM
(0.10 mL, 0.001 mol) was added. To this solution respective
substituted phenyl isocyanates or isothiocyanates
(0.0012 mol) were added drop-wise while maintaining the
temperature at 0 C. The reaction mixture was stirred for
8 h slowly warming to room temperature. DMF was evap-
orated under high vacuum and the residue was poured into
about 50 mL ice-cold 90% saturated KHCO3 solution and
stirred for 30 min. The precipitate was extracted into chlo-
roform and washed sequentially with 5% NaHCO3 solution
(2 · 10 mL), water (2 · 10 mL), 0.1 N citric acid (2 · 10 mL)
followed by brine. The organic layer was dried over anhy-
drous Na2SO4. The solvent was removed under reduced
pressure, triturated with hexane ﬁltered and dried under
vacuum.
2.2.3. General procedure for side chain deprotection of OBzl of
Glu, 2,6-Cl2-Bzl of Tyr and Z of Lys (56–91)
To a solution of the derivatives (0.001 mol) in methanol
(10 mL/g of compound), 10% Pd–C (100 mg) and ammo-
nium formate (1 g) were added and the mixture was stir-
red at room temperature for 2 h. After completion of
the reaction monitored by TLC, catalyst was ﬁltered
S250 D.M. Suyoga Vardhan et al.and washed with methanol. The solvent was evaporated
under reduced pressure and the product was taken into
CHCl3, washed with saturated NaCl and the solvent
was dried over anhydrous Na2SO4. The solvent was re-
moved under reduced pressure and triturated with ether,
ﬁltered and dried to get side chain deprotected deriva-
tives (56–91).
2.3. Pharmacology
Antiglycation assay (in vitro) [20]. Sodium phosphate buffer
(pH 7.4) was prepared by mixing Na2HPO4 and NaH2PO4
(67 mM) containing sodium azide (3 mM); phosphate buffer
saline (PBS) was prepared by mixing NaCl (137 mM) + Na2-
HPO4 (8.1 mM) + KCl (2.68 mM) + KH2PO4 (1.47 mM)
and pH 10 was adjusted with NaOH (0.25 mM), while BSA
(10 mg/mL) and anhydrous glucose (50 mg/mL) solutions were
prepared in sodium phosphate buffer. Eppendorf tubes (Tar-
sons, India) were used for incubation.
Bovine serum albumin (10 mg/mL) and glucose anhydrous
(50 mg/mL) were prepared in sodium phosphate buffer (pH
7.4). DMSO used for dissolving the compounds was found
to have no effect on the reaction at <2% (v/v). Glycated con-R =
1
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Scheme 1 Schematic representation of the synthesis of ureido/thio
piperazine. Reagents and conditions: (a) EDCI/HOBt, NMM, 0 C
isocyanates/isothiocyanates, NMM, THF, 8 h, 0 C to rt; R = Side ctrol contains 20 lL BSA+ 20 lL glucose + 20 lL sodium
phosphate buffer, blank control contains 20 lL BSA and
40 lL sodium phosphate buffer, while the test contains 20 lL
BSA+ 20 lL glucose + 20 lL compound ranging from 0.5
to 500 lg/mL concentration. All the incubation tubes
containing the mixtures were sealed and incubated at 37 C
for 7 days. After incubation, 6 lL (100%) of TCA was added
into each tube and centrifuged (15,000 rpm) for 4 min at 4 C.
After centrifugation, the pellets were rewashed with 60 lL
(10%) of TCA. The supernatant containing glucose, inhibitor
and interfering substance was removed and pellet containing
advanced glycated end product-BSA was dissolved in 60 lL
phosphate buffer solution (PBS) and transferred into 96-well
ELISA plates (Tarsons, India). Evaluation of ﬂuorescence
spectrum (excitation 370 nm), and change in ﬂuorescence
intensity (excitation 370 nm to emission 440 nm), based on
AGEs were monitored by using spectroﬂuorimeter (RF-1500,
Shimadzu, Japan). % Inhibition was calculated using the
formula:%Inhibition ¼ 1 Fluorescence of sample
Fluorescence of glycated sample
 1004
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ureido derivatives of amino acid-conjugated 2,3-dichlorophenyl
; (b) TFA, 40 min, rt; (c) HCOONH4/10% Pd–C; (d) Phenyl
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Table 1 Physical and mass data of the synthesized compounds.
Entry R X Rf
a Rf
b Yield (%) MP (C) Mol. For. Mass (M+ 1)
8 H O 0.58 0.69 91.5 Gum C26H26Cl2N4O2 483.1
9 H S 0.54 0.65 92.6 Gum C26H26Cl2N4OS 499.1
10 2Br S 0.53 0.62 94.2 62–65 C26H25Cl2BrN4OS 578.0
11 3Br O 0.56 0.69 92.5 84–86 C26H25Cl2BrN4O2 562.0
12 3Br S 0.53 0.66 90.3 63–65 C26H25Cl2BrN4OS 578.0
13 4Br O 0.52 0.67 94.2 75–77 C26H25Cl2BrN4O2 562.4
14 3F O 0.54 0.65 90.5 89–91 C26H25Cl2FN4O2 501.1
15 4F O 0.55 0.63 92.5 87 C26H25Cl2FN4O2 501.1
16 4F S 0.51 0.62 94.5 Gum C26H25Cl2FN4OS 517.1
17 3Cl O 0.53 0.63 90.4 90 C26H25Cl3N4O2 515.0
18 3Cl S 0.56 0.68 96.5 Gum C26H25Cl3N4OS 533.0
19 4Cl S 0.52 0.67 87.5 72 C26H25Cl3N4OS 532.0
20 H O 0.45 0.56 90.4 95 C29H30Cl2N4O4 569.1
21 H S 0.42 0.51 86.3 82 C29H30Cl2N4O3S 585.1
22 2Br S 0.48 0.52 90.7 58 C29H29Cl2BrN4O3S 664.0
664.5
23 3Br O 0.44 0.53 94.7 70–72 C29H29Cl2BrN4O4 648.0
648.1
24 3Br S 0.41 0.54 90.8 62 C29H29Cl2BrN4O3S 664.5
664.6
25 4Br O 0.43 0.57 94.5 65 C29H29Cl2BrN4O4 648.0
648.2
26 3F O 0.40 0.55 92.5 75 C29H29Cl2FN4O4 587.1
27 4F O 0.46 0.59 94.3 78–80 C29H29Cl2FN4O4 587.1
28 4F S 0.43 0.56 91.4 67–69 C29H29Cl2FN4O3S 604.1
29 3Cl O 0.41 0.54 93.2 78 C29H29Cl3N4O4 604.1
30 3Cl S 0.44 0.57 88.5 70–72 C29H29Cl3N4O3S 619.1
31 4Cl S 0.42 0.58 95.3 74 C29H29Cl2FN4O3S 619.1
32 H O 0.62 0.71 90.2 75 C33H30Cl4N4O3 671.1
33 H S 0.59 0.69 94.5 68 C33H30Cl4N4O2S 687.3
34 2Br S 0.58 0.68 88.6 58–60 C33H29Cl4BrN4O2S 766.0
766.3
35 3Br O 0.63 0.71 86.2 68–70 C33H29Cl4BrN4O3 750.0
750.5
36 3Br S 0.64 0.72 92.3 60 C33H29Cl4BrN4O2S 765.9
765.5
37 4Br O 0.61 0.70 86.3 72 C33H29Cl4BrN4O3 750.0
750.5
38 3F O 0.60 0.69 94.0 115–118 C33H29Cl4FN4O3 689.1
39 4F O 0.58 0.68 92.1 120–123 C33H29Cl4FN4O3 689.1
40 4F S 0.63 0.71 96.3 75 C33H29Cl4FN4O2S 705.1
41 3Cl O 0.65 0.73 89.3 110–112 C33H29Cl5N4O3 705.1
42 3Cl S 0.64 0.72 94.2 95 C33H29Cl5N4O3 721.0
43 4Cl S 0.62 0.70 87.5 98–100 C33H29Cl5N4O2S 721.1
44 H O 0.54 0.60 94.3 Gum C31H35Cl2N5O4 612.2
45 H S 0.52 0.59 96.0 Gum C31H35Cl2N5O3S 628.1
46 2Br S 0.53 0.61 88.3 67–70 C31H34Cl2BrN5O3S 707.1
707.4
47 3Br O 0.54 0.63 89.2 78 C31H34Cl2BrN5O4 691.6
691.3
48 3Br S 0.56 0.62 90.3 71 C31H34Cl2BrN5O3S 707.1
707.5
49 4Br O 0.52 0.59 92.5 73 C31H34Cl2BrN5O4 691.8
691.5
50 3F O 0.55 0.60 95.6 Gum C31H34Cl2FN5O4 630.2
51 4F O 0.54 0.62 87.4 Gum C31H34Cl2FN5O4 630.2
52 4F S 0.57 0.64 95.2 Gum C31H34Cl2FN5O3S 646.1
53 3Cl O 0.50 0.59 91.3 92 C31H34Cl3N5O4 646.1
54 3Cl S 0.54 0.62 89.5 84–86 C31H34Cl3N5O3S 662.1
(continued on next page)
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Figure 1 General features of the compounds proposed in this work.
Table 1 (continued)
Entry R X Rf
a Rf
b Yield (%) MP (C) Mol. For. Mass (M+ 1)
55 4Cl S 0.51 0.60 93.2 82 C31H34Cl3N5O3S 662.1
56 H O 0.31 0.45 86.5 90 C22H24Cl2N4O4 479.1
57 H S 0.33 0.42 92.5 84–86 C22H24Cl2N4O3S 495.0
58 2Br S 0.35 0.48 93.2 82 C22H23Cl2BrN4O3S 574.0
574.2
59 3Br O 0.32 0.44 90.2 85 C22H23Cl2BrN4O4 558.0
558.3
60 3Br S 0.30 0.41 87.5 78–80 C22H23Cl2BrN4O3S 574.1
574.5
61 4Br O 0.32 0.43 93.5 87 C22H23Cl2BrN4O4 558.0
558.2
62 3F O 0.34 0.40 89.3 71 C22H23Cl2FN4O4 497.1
63 4F O 0.33 0.46 86.5 68–70 C22H23Cl2FN4O4 497.1
64 4F S 0.30 0.43 95.6 78 C22H23Cl2FN4O3S 513.1
65 3Cl O 0.31 0.41 89.5 88 C22H23Cl3N4O4 513.0
66 3Cl S 0.34 0.44 95.6 74 C22H23Cl3N4O3S 529.1
67 4Cl S 0.32 0.42 90.5 76–78 C22H23Cl3N4O3S 529.1
68 H O 0.54 0.60 92.5 105 C26H26Cl2N4O3 512.1
69 H S 0.51 0.59 93.4 88–90 C26H26Cl2N4O2S 529.1
70 2Br S 0.49 0.62 89.5 118 C26H25Cl2BrN4O2S 608.0
608.2
71 3Br O 0.52 0.58 89.5 143 C26H25Cl2BrN4O3 592.0
592.4
72 3Br S 0.53 0.60 90.6 120 C26H25Cl2BrN4O2S 608.1
608.5
73 4Br O 0.50 0.59 89.6 132 C26H25Cl2BrN4O3 592.0
592.4
74 3F O 0.54 0.62 90.2 152 C26H25Cl2FN4O3 531.4
75 4F O 0.52 0.58 88.9 154 C26H25Cl2FN4O3 531.3
76 4F S 0.51 0.59 92.5 145–147 C26H25Cl2FN4O2S 547.4
77 3Cl O 0.53 0.61 94.6 135–137 C26H25Cl3N4O3 548.8
78 3Cl S 0.51 0.59 95.7 114 C26H25Cl3N4O2S 563.9
79 4Cl S 0.52 0.60 93.5 114–116 C26H25Cl3N4O2S 563.8
80 H O 0.43 0.54 89.6 Gum C23H29Cl2N5O2 478.4
81 H S 0.40 0.55 87.2 Gum C23H29Cl2N5OS 494.4
82 2Br S 0.42 0.51 94.5 60 C23H28Cl2BrN5OS 574.3
574.4
83 3Br O 0.41 0.53 92.5 65 C23H28Cl2BrN5O2 557.1
557.5
84 3Br S 0.43 0.56 95.7 58 C23H28Cl2BrN5OS 574.3
574.6
85 4Br O 0.42 0.50 93.6 70 C23H28Cl2BrN5O2 557.1
557.4
86 3F O 0.41 0.52 88.3 Gum C23H28Cl2FN5O2 496.4
87 4F O 0.45 0.55 89.4 Gum C23H28Cl2FN5O2 496.3
88 4F S 0.40 0.52 91.2 Gum C23H28Cl2FN5OS 512.4
89 3Cl O 0.43 0.50 92.8 72 C23H28Cl3N5O2 512.8
90 3Cl S 0.45 0.53 94.1 Gum C23H28Cl3N5OS 528.9
91 4Cl S 0.43 0.55 92.4 Gum C23H28Cl3N5OS 528.8
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Synthesis and evaluation of novel ureido/thioureido derivatives S2533. Results and discussion
In the present study we have synthesized four series of disub-
stituted urea and thiourea derivatives. The synthesis was
started by conjugating piperazine moiety to different amino
acids using EDCI/HOBt as coupling agent and NMM as base.
TLC indicated the completion of the reaction. Further the
conjugation was conﬁrmed by the absence of the –COOH
group and appearance of the amide group (CONH) in the
PMR spectrum. The Boc group of the conjugates was removed
using TFA (which was conﬁrmed by TLC) and was further re-
acted with respective substituted phenyl isocyanates/isothiocy-
anates to get the title compounds. Further, OBzl of Glu, 2,6-
Cl2-Bzl of Tyr and Z of Lys were removed by HCOONH4/
10% Pd–C to obtain corresponding side chain free derivatives
(Scheme 1). Yields of the compounds were found to be >85%.
All the synthesized compounds were characterized by IR, 1H
NMR, mass and elemental analysis. IR spectra of the ureas
and thioureas exhibited peaks at m 1620 cm1 and
2040 cm1 for C‚O and C‚S respectively. 1H NMR spec-
tra showed singlet for NH at d  8.75 and multiplet for an-
other –NH proton at d  8.31 for urea derivatives. On the
other hand, d singlet at 9.70 (NH) and multiplet at
d  8.49 (NH) were observed for thiourea derivatives. Further,
all the other peaks were exactly matching the structure. Also
% of each element (C, H, N and S) of the synthesized com-
pounds was conﬁrmed by elemental analysis and the values
are found to be within ±0.4% of the calculated ones. The
physical and mass data of the derivatives are presented in Ta-
ble 1. Structural IR and 1H NMR data have been provided as
Supplementary Data.
From our previous investigations we knew that the
amide bond (obtained by conjugating amino acids/peptides
with heterocycle) [29–31] is beneﬁcial for enhancing the bio-
logical properties. Therefore we ﬁrst started with the conju-
gation of amino acids with 2,3-dichlorophenyl piperazine to
obtain hybrid molecules 1–7. To get the structural feature
shown in Fig. 1 it was necessary to introduce NH–CO–
NH/NH–CS–NH groups by using amino acids and isocya-
nates/isothiocyanates. The resultant 84 title compounds
were subjected to antiglycation activity and the data are
presented in Table 2. Rutin served as positive control in
the assay with IC50 41.9 lM.
In the earlier work [37], it was noticed that compounds
containing simple amino acids like glycine and proline
revealed promising antiglycation activity. Further, it was
observed that the presence of electron withdrawing substitu-
ents enhances the activity compared to electron donating
groups. This formed the basis for the present work wherein,
we have chosen representative amino acid from different
classes and also felt necessary to consider only electron with-
drawing groups.
In this direction, we have synthesized a small library of
84 compounds in order to identify potent antiglycating
agents. Among the amino acids, compounds containing
Glu (20–31/56–67) and Tyr (32–43/68–79) showed a signiﬁ-
cant improvement in the activity compared to Phe (8–19)
and Lys (44–55/80–91) analogues. From this it can be in-
ferred that the presence of acidic instead of basic amino
acid and phenolic instead of the phenyl group containing
amino acid is favorable for better antiglycation activity.
Figure 2 Diagrammatic representation of antiglycation activity of urea and thiourea derivatives of compounds with no substitution.
Figure 3 Diagrammatic representation of antiglycation activity of urea and thiourea derivatives of phenylalanine containing
compounds.
S254 D.M. Suyoga Vardhan et al.In medicinal chemistry thiourea moiety is considered as iso-
stere for urea bond possessing more rigidity and stability
[5,7]. Further several articles [17,1] report that compounds
containing the thiourea group exhibit more activity than
urea. So, we synthesized two sets of compounds containing
these functionalities. It was noticed that there was no dif-
ference in activity if O of urea is replaced by S. Hence,
it may be inferred that for this set of compounds both urea
and thiourea groups hold promise signiﬁcantly in protein
glycation.
As a next step, we varied substituents of different electro-
negativities on the aromatic ring of the phenyl isocyanates/isothiocyanates. It was noticed that the activity is electroneg-
ativity dependent i.e., compounds containing halogen moie-
ties (10–19, 22–31/58–67, 34–43/70–79, 46–55/82–91)
exerted highly potent activity than the compounds without
halogen on the aromatic ring of the urea/thiourea group
(8, 9, 20, 21, 32, 33, 44, 45, 56, 57, 68, 69, 80, 81). This re-
vealed that the presence of halogen is very much essential
for good activity [18]. Further the compounds have demon-
strated that polarity plays a role in the inhibition studies.
This is supported by the fact that compounds having free
amino acid side chain (56–67, 68–79 and 80–91) have shown
enhanced activity compared to those compounds bearing
Figure 4 Diagrammatic representation of antiglycation activity of urea and thiourea derivatives of glutamic acid containing compounds.
Figure 5 Diagrammatic representation of antiglycation activity of urea and thiourea derivatives of tyrosine containing compounds.
Synthesis and evaluation of novel ureido/thioureido derivatives S255side chain protected amino acids (20–31, 32–43 and 44–51)
which is in accordance with the earlier article [36]
(Figs. 2–6). In Fig. 2, it may be observed that compounds
having no substitution displayed high IC50 values compared
to standard rutin. Fig. 3 explains the activity proﬁle
obtained for phenylalanine derivatives. It can be seen that
those derivatives possessing Cl and F substitutions exhibited
high activity. Figs. 4–6 explain more or less the same trend
of activity fetched for Glu, Tyr and Lys derivatives respec-
tively. It is clearly seen that compounds after deprotection
of the side chain functions possessed high activity compared
to their counterparts.4. Conclusion
The current study demonstrates the structure–activity guided
synthesis of antiglycating agents. We further developed the
general scaffold of the title compounds with respect to
glycation inhibition studies. The resulting analogues showed
an up to 20-fold higher activity than the reference com-
pound. The activity was dependent on the amino acids.
Moreover, the data demonstrated that halogen substituent
on the aromatic ring was favorable for activity. On the other
hand, the presence of side chain free amino acids in the
Figure 6 Diagrammatic representation of antiglycation activity of urea and thiourea derivatives of lysine containing compounds.
S256 D.M. Suyoga Vardhan et al.compounds possessed enhanced activity. However, the
results showed that the compounds containing both urea
and thiourea groups signiﬁcantly inhibit protein glycation.
The results obtained in this work further encourage us to
continue in this line.
Appendix A. Supplementary data
Supplementary data associated with this article can be found,
in the online version, at http://dx.doi.org/10.1016/j.jscs.2014.
02.006.
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